Jazz Pharmaceuticals Analysis Reveals THC And CBD Therapy Alleviates MS Spasticity
Portfolio Pulse from Nicolás Jose Rodriguez
A new analysis of two clinical trials reveals that Nabiximols, a cannabis-based oral spray developed by GW Pharmaceuticals (now part of Jazz Pharmaceuticals), significantly relieves spasticity in multiple sclerosis (MS) patients. The therapy, marketed as Sativex, is approved for treating MS-related spasticity in many countries, excluding the United States.
May 26, 2023 | 3:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jazz Pharmaceuticals' Nabiximols, a cannabis-based oral spray, has been found to significantly relieve spasticity in multiple sclerosis patients, according to a new analysis of two clinical trials.
The new analysis provides robust evidence of Nabiximols' efficacy in reducing spasticity associated with MS. This positive result may lead to increased demand for the therapy and potential expansion into the US market, which could positively impact Jazz Pharmaceuticals' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100